Summary
- Sidley has successfully represented Aquestive Therapeutics, Inc. in an exclusive licensing agreement with Eton Pharmaceuticals, Inc. for the commercialization of Libervant® (diazepam) buccal film.
- This orphan-designated treatment targets seizure clusters in epilepsy patients and is projected to tap into a U.S. market worth over US$450 million annually.
- The agreement grants Eton exclusive rights to market Libervant in the United States, with a commercial launch expected in April 2027, pending FDA approval.
- Led by Jennifer Raab, the Sidley team is poised to navigate this significant deal that could reshape treatment options for epilepsy patients.
Join the discussion — sign up to comment, upvote, and save articles.